VIR Long Call Strategy
VIR (Vir Biotechnology, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
VIR (Vir Biotechnology, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.57B, a beta of 1.70 versus the broader market, a 52-week range of 4.155-11.66, average daily share volume of 3.6M, a public-listing history dating back to 2019, approximately 408 full-time employees. These structural characteristics shape how VIR stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.70 indicates VIR has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long call on VIR?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current VIR snapshot
As of May 15, 2026, spot at $8.77, ATM IV 62.20%, IV rank 8.95%, expected move 17.83%. The long call on VIR below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 63-day expiry.
Why this long call structure on VIR specifically: VIR IV at 62.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a VIR long call, with a market-implied 1-standard-deviation move of approximately 17.83% (roughly $1.56 on the underlying). The 63-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated VIR expiries trade a higher absolute premium for lower per-day decay. Position sizing on VIR should anchor to the underlying notional of $8.77 per share and to the trader's directional view on VIR stock.
VIR long call setup
The VIR long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With VIR near $8.77, the first option leg uses a $9.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed VIR chain at a 63-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 VIR shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $9.00 | $0.85 |
VIR long call risk and reward
- Net Premium / Debit
- -$85.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$85.00
- Breakeven(s)
- $9.85
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
VIR long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on VIR. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -99.9% | -$85.00 |
| $1.95 | -77.8% | -$85.00 |
| $3.89 | -55.7% | -$85.00 |
| $5.82 | -33.6% | -$85.00 |
| $7.76 | -11.5% | -$85.00 |
| $9.70 | +10.6% | -$15.01 |
| $11.64 | +32.7% | +$178.79 |
| $13.58 | +54.8% | +$372.59 |
| $15.51 | +76.9% | +$566.39 |
| $17.45 | +99.0% | +$760.19 |
When traders use long call on VIR
Long calls on VIR express a bullish thesis with defined risk; traders use them ahead of VIR catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
VIR thesis for this long call
The market-implied 1-standard-deviation range for VIR extends from approximately $7.21 on the downside to $10.33 on the upside. A VIR long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current VIR IV rank near 8.95% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on VIR at 62.20%. As a Healthcare name, VIR options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to VIR-specific events.
VIR long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. VIR positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move VIR alongside the broader basket even when VIR-specific fundamentals are unchanged. Long-premium structures like a long call on VIR are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current VIR chain quotes before placing a trade.
Frequently asked questions
- What is a long call on VIR?
- A long call on VIR is the long call strategy applied to VIR (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With VIR stock trading near $8.77, the strikes shown on this page are snapped to the nearest listed VIR chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are VIR long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the VIR long call priced from the end-of-day chain at a 30-day expiry (ATM IV 62.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$85.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a VIR long call?
- The breakeven for the VIR long call priced on this page is roughly $9.85 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current VIR market-implied 1-standard-deviation expected move is approximately 17.83%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on VIR?
- Long calls on VIR express a bullish thesis with defined risk; traders use them ahead of VIR catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current VIR implied volatility affect this long call?
- VIR ATM IV is at 62.20% with IV rank near 8.95%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.